Abstract
Pakistan Registry of Intensive Care (PRICE) is a platform that has enabled standardized COVID-19 clinical data collection based on ISARIC/WHO Clinical Characterization Protocol. The near real-time data platform includes epidemiology, severity of illness, microbiology, treatment and outcomes of patients admitted with suspected or laboratory confirmed COVID19 infection to 67 intensive care and high dependency units across the country. Data has been extracted and analysed at regular intervals to inform stakeholders and improve care practices. This is our 28th report including all patients with suspected or confirmed COVID-19 from 26th March 2020 to 26th December 2021.
Key findings from 8624 patients who met eligibility criteria, are as follows:
⍰ Median age of 60 years (IQR 50-70).
⍰ The most common symptoms were shortness of breath (n = 6428, 77.8%), fever (n = 6091, 73.8%), and Cough (n = 3354, 38.9%)
⍰ The most common comorbidity was hypertension followed by diabetes.
⍰ During the course of illness 2804 (32.6%) patients received non-invasive ventilation, whereas 2474 (28.8%) patients had mechanical ventilation as their highest organ support. In addition, 2246 (26.1%) patients needed haemodynamic support and 1249 (14.7%) patients required renal replacement therapy as their highest organ support.
⍰ Median APACHE II score was 18
⍰ Overall mortality at ICU discharge was 39.2%
⍰ Increasing age and requirement for invasive mechanical ventilation were independent risk factors for mortality increased the risk of death
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PRICE, a founding member of CRIT Care Asia is funded by Wellcome Innovations grant awarded to Oxford University (award code) 215522 and by ISARIC grant (222048/Z/20/Z)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Bioethics Committee of Pakistan gave ethical Approval for this work Ref: No.4-87/NBC-470/COVID01-/20/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Writing committee: Thalha Rashan, Aasiyah Rashan, Rashan Haniffa, Abigail Beane
Data Availability
All data produced in the present work are contained in the manuscript